Evaluation of Screening Program for Hepatitis C Virus (HCV) At AST Pesaro-Urbino: First Year Results

Raffaele La Porta*; Antonio Vitiello; Annalisa Belli; Davide Sisti; Andrea Zovi; Francesca Bruscolini; Saverio Guerra; Sara Carbonari; Sara Di Benedetto; Tania Rodini; Simone Barocci; Stefano Amatori

Raffaele La Porta*, Antonio Vitiello, Annalisa Belli, Davide Sisti, Andrea Zovi, Francesca Bruscolini, Saverio Guerra, Sara Carbonari, Sara Di Benedetto, Tania Rodini, Simone Barocci and Stefano Amatori

Volume6-Issue1
Dates: Received: 2025-01-08 | Accepted: 2025-01-27 | Published: 2025-01-31
Pages: 107-116

Abstract

Background: Hepatitis C virus (HCV) infection is the leading cause of chronic liver disease worldwide. In 2016, the World Health Organization (WHO) launched a global-screening initiative aimed at eliminating HCV as a public health threat by 2030. In Italy, the national screening program targeted all people born between 1969 and 1989. This study reports on an HCV screening program conducted within the population served by AST Pesaro-Urbino of the Marche region, central Italy.

Methods: This prospective study was conducted within the AST Pesaro-Urbino, following the launch of an HCV screening campaign in July 2023. The program targeted all individuals born between 1969 and 1989. Between August 2023 and July 2024, all subjects were submitted to anti-HCV tests, and those testing positive were subsequently tested for HCV-RNA test.

Results: Six blood collection centers participated in the HCV screening campaign. A total of 12.4% of the target population born between 1969 and 1989 was screened, corresponding to 6,319 individuals, of whom 2,579 (40.8%) were males and 3,740 (59.2%) were females. Among those screened, 64 individuals (1.0%; 35 males and 29 females) tested positive for anti-HCV antibodies. Of these, 8 individuals (0.13%; 5 males and 3 females) were confirmed to be HCV-RNA positive. This screening program allowed us to obtain a prevalence of viremic infections of 0.13%.

Conclusion: The prevalence of active HCV infection in the sample tested from 1969-1989 present in the territory of AST Pesaro-Urbino is remarkably low, at 0,13%; prevalence either represents true population value or could be due at a biased sample.

FullText HTML FullText PDF DOI: 10.37871/jbres2061

Certificate of Publication

Copyright

How to cite this article

La Porta R, Vitiello A, Belli A, Sisti D, Zovi A, Bruscolini F, Guerra S, Carbonari S, Di Benedetto S, Rodini T, Barocci S, Amatori S. Evaluation of Screening Program for Hepatitis C Virus (HCV) At AST Pesaro- Urbino: First Year Results. J Biomed Res Environ Sci. 2025 Jan 31; 6(1): 107-116. doi: 10.37871/jbres2061, Article ID: JBRES2061, Available at: https://www.jelsciences.com/articles/jbres2061.pdf

Subject area(s)

Epidemiology

References

D'souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020 Oct 14;26(38):5759-5783. doi: 10.3748/wjg.v26.i38.5759. PMID: 33132633; PMCID: PMC7579760.
Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):637-656. doi: 10.51821/84.4.015. PMID: 34965046.
Martinez MA, Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses. 2020 Dec 29;13(1):41. doi: 10.3390/v13010041. PMID: 33383891; PMCID: PMC7824680.
Mohamed EA, Giama NH, Abdalla AO, Shaleh HM, Oseini AM, Ali HA, Ahmed F, Taha W, Ahmed Mohammed H, Cvinar J, Waaeys IA, Ali H, Allotey LK, Ali AO, Mohamed SA, Harmsen WS, Ahmmad EM, Bajwa NA, Afgarshe MD, Shire AM, Balls-Berry JE, Roberts LR. High prevalence of chronic viral hepatitis B and C in Minnesota Somalis contributes to rising hepatocellular carcinoma incidence. World J Gastroenterol. 2022 Sep 21;28(35):5217-5229. doi: 10.3748/wjg.v28.i35.5217. PMID: 36188718; PMCID: PMC9516675.
Lazarus JV, Picchio CA, Colombo M. Hepatocellular Carcinoma Prevention in the Era of Hepatitis C Elimination. Int J Mol Sci. 2023 Sep 21;24(18):14404. doi: 10.3390/ijms241814404. PMID: 37762706; PMCID: PMC10531569.
Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. doi: 10.1016/S2468-1253(21)00472-6. Epub 2022 Feb 16. PMID: 35180382.
Spada E, Marcantonio C, Vescio MF, Marascio N, Villano U, Pisani G, Tritarelli E, Bruni R, Barreca GS, Torti C, Matera G, Liberto MC, Focà A, Pezzotti P, Ciccaglione AR; Viral Hepatitis ISS-UNICZ study group. Changing epidemiology of hepatitis C in Italy: a population-based survey in a historically high endemic area. Minerva Med. 2023 Apr;114(2):191-202. doi: 10.23736/S0026-4806.21.07280-3. Epub 2021 Apr 29. PMID: 33913660.
D'Ambrosio R, Anolli MP, Pugliese N, Masetti C, Aghemo A, Lampertico P. Prevalence of HCV infection in Europe in the DAA era: Review. Liver Int. 2024 Jul;44(7):1548-1563. doi: 10.1111/liv.15981. Epub 2024 May 28. PMID: 38804727.
Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi A, Brancaccio G, Coco C, Russello M, Smedile A, Petrini E, Martini S, Gaeta GB, Rizzetto M. Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. Eur J Intern Med. 2018 Jul;53:79-84. doi: 10.1016/j.ejim.2018.02.015. Epub 2018 Feb 21. PMID: 29475770.
Stasi C, Silvestri C, Voller F. Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination. SN Compr Clin Med. 2020;2(12):2808-2815. doi: 10.1007/s42399-020-00588-3. Epub 2020 Oct 18. PMID: 33103061; PMCID: PMC7568689.
Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res. 2014 Jun 19;6:303-10. doi: 10.2147/CEOR.S62092. PMID: 24971024; PMCID: PMC4069043.
Mele A, Ferrigno L, Romanò L, Alfonsi V, D'Angelo F, Crateri S, Tosti ME; Gruppo di collaborazione SEIEVA. Aggiornamento sull’epidemiologia dell’epatite A in Italia negli ultimi cinque anni. Dati dalla sorveglianza SEIEVA 2015-2019 [An update on the epidemiology of hepatitis A in Italy 2015-2019. Data from the surveillance of acute viral hepatitis SEIEVA]. Epidemiol Prev. 2021 May-Jun;45(3):173-180. Italian. doi: 10.19191/EP21.3.P173.062. PMID: 34212698.
Kondili LA, Andreoni M, Aghemo A, Mastroianni CM, Merolla R, Gallinaro V, Craxì A. Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian regions: a mathematical modelling approach by route of transmission and fibrosis progression with results up to January 2021. New Microbiol. 2022 Dec;45(4):249-259. Epub 2022 May 25. PMID: 36066213.
Stasi C, Silvestri C, Berni R, Rossana Brunetto M, Zignego AL, Orsini C, Milani S, Ricciardi L, De Luca A, Blanc P, Nencioni C, Aquilini D, Bartoloni A, Bresci G, Marchi S, Filipponi F, Colombatto P, Forte P, Galli A, Luchi S, Chigiotti S, Nerli A, Corti G, Sacco R, Carrai P, Ricchiuti A, Giusti M, Almi P, Cozzi A, Carloppi S, Laffi G, Voller F, Cipriani F. Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. Curr Med Res Opin. 2019 Apr;35(4):661-666. doi: 10.1080/03007995.2018.1482264. Epub 2018 Jun 26. PMID: 29847179.
Rossetti B, Bai F, Tavelli A, Galli M, Antinori A, Castelli F, Pellizzer G, Cozzi-Lepri A, Bonora S, Monforte AD, Puoti M, De Luca A; ICONA Foundation study group. Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. Clin Microbiol Infect. 2018 Apr;24(4):422-427. doi: 10.1016/j.cmi.2017.07.021. Epub 2017 Jul 29. PMID: 28765078.
https://www.gazzettaufficiale.it/eli/id/2020/02/29/20G00021/sg (accessed on 24 November 2023).
Songtanin B, Nugent K. Burden, Outcome, and Comorbidities of Extrahepatic Manifestations in Hepatitis C Virus Infection. Biology (Basel). 2022 Dec 22;12(1):23. doi: 10.3390/biology12010023. PMID: 36671716; PMCID: PMC9855523.
Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 Oct 2;6(10):e2338792. doi: 10.1001/jamanetworkopen.2023.38792. PMID: 37862013; PMCID: PMC10589813.
Krawczyk A, Hintze C, Ackermann J, Goitowski B, Trippler M, Grüner N, Neumann-Fraune M, Verheyen J, Fiedler M. Clinical performance of the novel DiaSorin LIAISON(®) XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays. J Clin Virol. 2014 Jan;59(1):44-9. doi: 10.1016/j.jcv.2013.10.009. Epub 2013 Nov 7. PMID: 24268764.
Guidelines on hepatitis B and C testing. WHO guidelines approved by the guidelines review committee. World Health Organization (WHO). 2017.
Romano C, Tortorella O, Dalla Mora L, Di Stasio D, Sellitto A, Adinolfi LE, Marrone A. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Front Immunol. 2022 Apr 11;13:882064. doi: 10.3389/fimmu.2022.882064. PMID: 35479086; PMCID: PMC9038215.
Di Stasio D, Lucchese A, Romano A, Adinolfi LE, Serpico R, Marrone A. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Clin Oral Investig. 2022 Aug;26(8):5409-5417. doi: 10.1007/s00784-022-04507-9. Epub 2022 Apr 27. PMID: 35477818; PMCID: PMC9381460.
Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses. 2018 Oct 6;10(10):545. doi: 10.3390/v10100545. PMID: 30301201; PMCID: PMC6213504.
Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi A, Brancaccio G, Coco C, Russello M, Smedile A, Petrini E, Martini S, Gaeta GB, Rizzetto M. Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. Eur J Intern Med. 2018 Jul;53:79-84. doi: 10.1016/j.ejim.2018.02.015. Epub 2018 Feb 21. PMID: 29475770.
Kondili LA, Andreoni M, Alberti A, Lobello S, Babudieri S, Roscini AS, Merolla R, Marrocco W, Craxì A. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. Epidemics. 2021 Mar;34:100442. doi: 10.1016/j.epidem.2021.100442. Epub 2021 Feb 11. PMID: 33607538.
Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int. 2020 Jul;40(7):1545-1555. doi: 10.1111/liv.14408. Epub 2020 Apr 2. PMID: 32078234; PMCID: PMC7384106.
Messina V, Pisaturo M, Alessio L, Russo A, Tripaldelli E, Petruzziello A, Annecchiarico A, Romano MR, Maggi P, Coppola N. Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project. J Infect Public Health. 2022 May;15(5):562-565. doi: 10.1016/j.jiph.2022.04.003. Epub 2022 Apr 12. PMID: 35461078.
Huang Y, Pan H, Gao Q, Lv P, Xu X, Zhao Z. The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations. Sci Rep. 2021 Apr 22;11(1):8689. doi: 10.1038/s41598-021-88138-2. PMID: 33888806; PMCID: PMC8062551.
D'Ambrosio R, Piccinelli S, Beccalli B, Spinetti A, Puoti M, Fagiuoli S, Magni CF, Vavassori A, Sacchi P, Castaldi S, Bombardieri G, Farina C, Buoro S, Amorosi A, Corradin M, Cereda D, Lampertico P; Regional HCV Working Group. A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969-1989 birth-cohort. Liver Int. 2023 Dec;43(12):2645-2656. doi: 10.1111/liv.15727. Epub 2023 Sep 16. PMID: 37715524.
D'Ambrosio R, Rizzardini G, Puoti M, Fagiuoli S, Anolli MP, Gabiati C, D'Amico F, Pasulo L, Restelli U, Colombo M, Lampertico P. Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination. Liver Int. 2022 May;42(5):1012-1016. doi: 10.1111/liv.15216. Epub 2022 Mar 12. PMID: 35220667; PMCID: PMC9115160.
Viganò M, Cerini F, Ridolfo S, Rumi MG. Hepatitis C virus screening in the 1969-1989 birth cohort: Is not enough! Liver Int. 2022 Aug;42(8):1915. doi: 10.1111/liv.15316. Epub 2022 Jun 6. PMID: 35596923.
Dettori S, Russo C, Mora S, Giacomini M, Taramasso L, Dentone C, Vena A, Bassetti M, Di Biagio A. Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2. J Community Health. 2022 Oct;47(5):800-805. doi: 10.1007/s10900-022-01111-6. Epub 2022 Jun 21. PMID: 35729474; PMCID: PMC9211782.
Rosato V, Kondili LA, Nevola R, Perillo P, Mastrocinque D, Aghemo A, Claar E. Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses. 2022 May 19;14(5):1096. doi: 10.3390/v14051096. PMID: 35632837; PMCID: PMC9143022.
Torre P, Annunziata M, Sciorio R, Coppola C, Masarone M, Persico M. Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno. Liver Int. 2022 Jun;42(6):1467-1469. doi: 10.1111/liv.15273. Epub 2022 Apr 23. PMID: 35395130; PMCID: PMC9115238.
Morisco F, Loperto I, Stroffolini T, Lombardo FL, Cossiga V, Guarino M, De Feo A, Caporaso N. Prevalence and risk factors of HCV infection in a metropolitan area in southern Italy: Tail of a cohort infected in past decades. J Med Virol. 2017 Feb;89(2):291-297. doi: 10.1002/jmv.24635. Epub 2016 Jul 27. PMID: 27431017.
Citarella A, Cammarota S, Bernardi FF, Coppola C, D'Antò M, Fogliasecca M, Giusto E, Masarone M, Salomone Megna A, Sellitto C, Servodio R, Smaldone M, Staiano L, Trama U, Conti V, Persico M. Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy. Life (Basel). 2020 Dec 18;10(12):359. doi: 10.3390/life10120359. PMID: 33352991; PMCID: PMC7766029.